The aim of this study is to analyze the features of development and clinical manifestations of organic emotional lability (OEL) in the post-stroke period, as well as to investigate the relationship between symptom severity, lesion localization, and symptom dynamics. The study involved 80 patients aged 45 to 75 years with ischemic stroke. Assessment tools included the PLACS scale, HADS, MMSE, clinical and neurological examination, and brain MRI data. According to the results, signs of OEL were identified in 60% of patients, predominantly in cases of frontal lobe and basal ganglia lesions. The main symptoms included unmotivated crying, sudden mood swings, and irritability. Patients with OEL showed significantly higher levels of anxiety and depression on the HADS scale (p < 0.01). Over a 30-day period, most patients showed positive symptom dynamics. Thus, organic emotional lability is a common post-stroke complication, and its timely diagnosis and comprehensive therapy contribute to improved rehabilitation outcomes.

We examined 75 patients who had suffered an ischemic stroke and exhibited cognitive impairments. Patients were categorized into three groups: those with subjective cognitive impairment (SCI), mild cognitive impairment (MCI), and moderate cognitive impairment (MoCI). Cognitive function was assessed using MMSE, MOCA, FAB, the “10 words” test, the Schulte test, and cognitive evoked potentials (P300). The results showed varying degrees of cognitive dysfunction depending on the severity group, with the most significant changes seen in the MoCI group.

Acute cerebral circulatory failure (ACF) is one of the most pressing problems of modern medicine and public health. It is necessary to apply certain evaluation systems - scales - to assess the condition of patients. The article describes the results of the study 85 patients with STEMI. The correct representation of each patient's condition allowed to reasonably set strategic and tactical treatment objectives, to weigh the potential risk and advantages of individual treatment methods in cases when the patient's condition is extremely severe and the probability of lethal outcome is high. The use of scales in the practice of a neurologist allows to increase the efficiency of decision-making in therapy, the effectiveness of predicting stroke outcomes, and to compare treatment methods.

OSOK bemorlarida kognitiv funksiyalarni pasayishi ko‘pincha gipoksiya va giperkapniya darajasi bilan bog‘liq. Tadqiqot davomida 100 nafar bemor 3 guruhga ajratildi: yengil, o‘rta va og‘ir OSOK. Kognitiv testlar (MoCA, MMSE) va emotsional holatni baholash (HADS shkalasi) asosida olingan natijalar ko‘rsatdiki, og‘ir OSOK guruhida kognitiv pasayish 68% hollarda, depressiya 55%, tashvish 47% hollarda aniqlangan. O‘rta og‘irlikdagi OSOK bemorlarida esa bu ko‘rsatkichlar mos ravishda 42%, 33% va 25% ni tashkil etdi. Statistik tahlil shuni ko‘rsatadiki, kognitiv pasayish darajasi bilan depressiv simptomlar o‘rtasida kuchli ijobiy korrelyatsiya mavjud (r=0.71, p<0.01). Bu natijalar OSOKni kompleks davolashda psixiatriya va psixoterapiya aralashuvlarini qo‘shish zarurligini ko‘rsatadi. Shuningdek, psixoterapevtik yondashuvlar bemorlarning hayot sifatini yaxshilashda muhim rol o‘ynaydi....

По мнению ведущих специалистов и с официальной точки зрения экспертных групп таких авторитетных учреждений, как Всемирная организация здравоохранения или Национальный институт старения США, болезнь Альцгеймера в настоящее время считается одним из наиболее распространенных заболеваний у лиц пожилого и старческого возраста и сопоставим по распространенности с инфарктами миокарда и головного мозга у пожилых людей (KF Jellinger et al., 1994).

COVID-19 has a wide range of clinical manifestations. During the pandemic, neurological manifestations were demonstrated in patients with COVID-19, including cognitive impairment. In a study conducted in Wuhan, Hubei Province, 36.4% of patients had some neurological manifestations, while central organs were more often affected (dizziness, headache, changes in consciousness, stroke, ataxia and epilepsy).